BEAM THERAPEUTICS INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.27 USD | -6.46% |
|
-11.76% | -21.20% |
| Apr. 04 | Beam Therapeutics Insider Sold Shares Worth $581,617, According to a Recent SEC Filing | MT |
| Apr. 04 | Beam Therapeutics Insider Sold Shares Worth $734,805, According to a Recent SEC Filing | MT |
Presenter SpeechGreg Harrison (Analysts)Welcome to the afternoon session of Day 2 of the Bank ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
22.74
USD
Average target price
49.54
USD
Spread / Average Target
+117.85%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.20% | 1.81B | |
| +1.71% | 43.84B | |
| +7.00% | 41.68B | |
| +44.87% | 41.25B | |
| -10.92% | 27.04B | |
| +6.82% | 25.53B | |
| -25.51% | 18.18B | |
| -2.46% | 12.29B | |
| +26.64% | 12.29B | |
| +7.78% | 11.15B |
- Stock Market
- Equities
- BEAM Stock
- News Beam Therapeutics Inc.
- Transcript : Beam Therapeutics Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 02
